Carrier-mediated hepatic uptake of a novel nonrenal excretion type uric acid generation inhibitor, Y-700

Yoshimichi Sai, Yukio Kato, Keiko Nakamura, Sayaka Kato, Tomohiro Nishimura, Yoshiyuki Kubo, Ikumi Tamai, Shu Yang, Zhuhan Hu, Ichimaro Yamada, Akira Tsuji

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Y-700, a novel xanthine oxidase inhibitor, was recently developed for the treatment of hyperuricemia and gout. Since the major elimination route of this compound is hepatic metabolism and excretion, the aim of the present study was to characterize the uptake mechanism of Y-700 in the liver, which is also the pharmacological target of Y-700. Efficient uptake of Y-700 was observed both in the liver in vivo and in isolated rat hepatocytes. The uptake was Na +-dependent, saturable and inhibited both by ATP-depressants and various organic anions. Indomethacin competitively inhibited Y-700 uptake, whereas the inhibitory effect of organic cations and nucleosides was not so remarkable. Saturable and Na+-dependent uptake of Y-700 was also observed in freshly isolated human hepatocytes. Uptake of Y-700 by sinusoidal membrane transporters, such as organic anion transporter (Oat) 2 and organic anion transporting polypeptide (OATP)-B, OATP-C, OATP-8, and Oatp1, could not be detected although uptake of Y-700 in the oocytes expressing sodium/taurocholate cotransporting polypeptide (NTCP) was slightly observed. In conclusion, active transport system(s), which specifically recognize certain types of anionic compounds, are involved in the hepatic uptake of Y-700 and, at least partially, relevant to its elimination from the circulation as well as delivery to pharmacological target.

Original languageEnglish
Pages (from-to)336-347
Number of pages12
JournalJournal of Pharmaceutical Sciences
Volume95
Issue number2
DOIs
Publication statusPublished - 2006 Feb
Externally publishedYes

Fingerprint

Uric Acid
Liver
Anions
Hepatocytes
Organic Anion Transporters
Pharmacology
1-(3-cyano-4-neopentyloxyphenyl)pyrazole-4-carboxylic acid
Hyperuricemia
Peptides
Membrane Transport Proteins
Xanthine Oxidase
Gout
Active Biological Transport
Nucleosides
Metabolism
Indomethacin
Oocytes
Cations
Rats
Adenosine Triphosphate

Keywords

  • Active transport
  • Cellular uptake
  • Distribution
  • Excretion
  • Hepatocytes
  • Membrane transport
  • Organic anion transporter
  • Transporters

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Chemistry(all)
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science

Cite this

Carrier-mediated hepatic uptake of a novel nonrenal excretion type uric acid generation inhibitor, Y-700. / Sai, Yoshimichi; Kato, Yukio; Nakamura, Keiko; Kato, Sayaka; Nishimura, Tomohiro; Kubo, Yoshiyuki; Tamai, Ikumi; Yang, Shu; Hu, Zhuhan; Yamada, Ichimaro; Tsuji, Akira.

In: Journal of Pharmaceutical Sciences, Vol. 95, No. 2, 02.2006, p. 336-347.

Research output: Contribution to journalArticle

Sai, Y, Kato, Y, Nakamura, K, Kato, S, Nishimura, T, Kubo, Y, Tamai, I, Yang, S, Hu, Z, Yamada, I & Tsuji, A 2006, 'Carrier-mediated hepatic uptake of a novel nonrenal excretion type uric acid generation inhibitor, Y-700', Journal of Pharmaceutical Sciences, vol. 95, no. 2, pp. 336-347. https://doi.org/10.1002/jps.20540
Sai, Yoshimichi ; Kato, Yukio ; Nakamura, Keiko ; Kato, Sayaka ; Nishimura, Tomohiro ; Kubo, Yoshiyuki ; Tamai, Ikumi ; Yang, Shu ; Hu, Zhuhan ; Yamada, Ichimaro ; Tsuji, Akira. / Carrier-mediated hepatic uptake of a novel nonrenal excretion type uric acid generation inhibitor, Y-700. In: Journal of Pharmaceutical Sciences. 2006 ; Vol. 95, No. 2. pp. 336-347.
@article{ea8f8b97699f419c877f68058611d128,
title = "Carrier-mediated hepatic uptake of a novel nonrenal excretion type uric acid generation inhibitor, Y-700",
abstract = "Y-700, a novel xanthine oxidase inhibitor, was recently developed for the treatment of hyperuricemia and gout. Since the major elimination route of this compound is hepatic metabolism and excretion, the aim of the present study was to characterize the uptake mechanism of Y-700 in the liver, which is also the pharmacological target of Y-700. Efficient uptake of Y-700 was observed both in the liver in vivo and in isolated rat hepatocytes. The uptake was Na +-dependent, saturable and inhibited both by ATP-depressants and various organic anions. Indomethacin competitively inhibited Y-700 uptake, whereas the inhibitory effect of organic cations and nucleosides was not so remarkable. Saturable and Na+-dependent uptake of Y-700 was also observed in freshly isolated human hepatocytes. Uptake of Y-700 by sinusoidal membrane transporters, such as organic anion transporter (Oat) 2 and organic anion transporting polypeptide (OATP)-B, OATP-C, OATP-8, and Oatp1, could not be detected although uptake of Y-700 in the oocytes expressing sodium/taurocholate cotransporting polypeptide (NTCP) was slightly observed. In conclusion, active transport system(s), which specifically recognize certain types of anionic compounds, are involved in the hepatic uptake of Y-700 and, at least partially, relevant to its elimination from the circulation as well as delivery to pharmacological target.",
keywords = "Active transport, Cellular uptake, Distribution, Excretion, Hepatocytes, Membrane transport, Organic anion transporter, Transporters",
author = "Yoshimichi Sai and Yukio Kato and Keiko Nakamura and Sayaka Kato and Tomohiro Nishimura and Yoshiyuki Kubo and Ikumi Tamai and Shu Yang and Zhuhan Hu and Ichimaro Yamada and Akira Tsuji",
year = "2006",
month = "2",
doi = "10.1002/jps.20540",
language = "English",
volume = "95",
pages = "336--347",
journal = "Journal of Pharmaceutical Sciences",
issn = "0022-3549",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Carrier-mediated hepatic uptake of a novel nonrenal excretion type uric acid generation inhibitor, Y-700

AU - Sai, Yoshimichi

AU - Kato, Yukio

AU - Nakamura, Keiko

AU - Kato, Sayaka

AU - Nishimura, Tomohiro

AU - Kubo, Yoshiyuki

AU - Tamai, Ikumi

AU - Yang, Shu

AU - Hu, Zhuhan

AU - Yamada, Ichimaro

AU - Tsuji, Akira

PY - 2006/2

Y1 - 2006/2

N2 - Y-700, a novel xanthine oxidase inhibitor, was recently developed for the treatment of hyperuricemia and gout. Since the major elimination route of this compound is hepatic metabolism and excretion, the aim of the present study was to characterize the uptake mechanism of Y-700 in the liver, which is also the pharmacological target of Y-700. Efficient uptake of Y-700 was observed both in the liver in vivo and in isolated rat hepatocytes. The uptake was Na +-dependent, saturable and inhibited both by ATP-depressants and various organic anions. Indomethacin competitively inhibited Y-700 uptake, whereas the inhibitory effect of organic cations and nucleosides was not so remarkable. Saturable and Na+-dependent uptake of Y-700 was also observed in freshly isolated human hepatocytes. Uptake of Y-700 by sinusoidal membrane transporters, such as organic anion transporter (Oat) 2 and organic anion transporting polypeptide (OATP)-B, OATP-C, OATP-8, and Oatp1, could not be detected although uptake of Y-700 in the oocytes expressing sodium/taurocholate cotransporting polypeptide (NTCP) was slightly observed. In conclusion, active transport system(s), which specifically recognize certain types of anionic compounds, are involved in the hepatic uptake of Y-700 and, at least partially, relevant to its elimination from the circulation as well as delivery to pharmacological target.

AB - Y-700, a novel xanthine oxidase inhibitor, was recently developed for the treatment of hyperuricemia and gout. Since the major elimination route of this compound is hepatic metabolism and excretion, the aim of the present study was to characterize the uptake mechanism of Y-700 in the liver, which is also the pharmacological target of Y-700. Efficient uptake of Y-700 was observed both in the liver in vivo and in isolated rat hepatocytes. The uptake was Na +-dependent, saturable and inhibited both by ATP-depressants and various organic anions. Indomethacin competitively inhibited Y-700 uptake, whereas the inhibitory effect of organic cations and nucleosides was not so remarkable. Saturable and Na+-dependent uptake of Y-700 was also observed in freshly isolated human hepatocytes. Uptake of Y-700 by sinusoidal membrane transporters, such as organic anion transporter (Oat) 2 and organic anion transporting polypeptide (OATP)-B, OATP-C, OATP-8, and Oatp1, could not be detected although uptake of Y-700 in the oocytes expressing sodium/taurocholate cotransporting polypeptide (NTCP) was slightly observed. In conclusion, active transport system(s), which specifically recognize certain types of anionic compounds, are involved in the hepatic uptake of Y-700 and, at least partially, relevant to its elimination from the circulation as well as delivery to pharmacological target.

KW - Active transport

KW - Cellular uptake

KW - Distribution

KW - Excretion

KW - Hepatocytes

KW - Membrane transport

KW - Organic anion transporter

KW - Transporters

UR - http://www.scopus.com/inward/record.url?scp=32644452742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32644452742&partnerID=8YFLogxK

U2 - 10.1002/jps.20540

DO - 10.1002/jps.20540

M3 - Article

VL - 95

SP - 336

EP - 347

JO - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

SN - 0022-3549

IS - 2

ER -